Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)

Exclusion Criteria

• •Women who are pregnant or likely to become so in the course of the study.
• •Patients not affiliated to a social security scheme.
• •Patients who are protected adults under the terms of the law (French Public Health Code).
• •Refusal to consent.
• •Patients for whom the diagnosis of HHT has not been confirmed clinically and/or by molecular biology.
• •Patients with an on-going infectious condition.
• •Participation in another clinical trial within the 28 days prior to inclusion.
• •Known hypersensitivity to the active ingredient or one of the excipients.
• •Known hypersensitivity to products of Chinese hamster ovary cells (CHO) or other human or humanized recombinant antibodies.
• •Patients who have incompletely filled in the nosebleed grids in the 3 months preceding the treatment.
• •Patients who do not present with nosebleeds with a monthly average duration over the 3 months preceding the treatment of more than 20 minutes ((duration M1 + duration M2 + duration M3) / 3). Remark: only the 3 months strictly preceding the treatment will be taken into account, even if the grids have been completed over a longer period.
• •Patients who have received Avastin® intravenously in the 6 months prior to inclusion.